Improving cancer survival is a key challenge identified in Improving Outcomes: A Strategy for Cancer ([@bib10]). Cancer survival estimates in England currently fall below those in many European countries across most cancer types ([@bib2]; [@bib30]; [@bib40]). It has been estimated that if cancer survival in England was made comparable to the European average then 5000 or more deaths within 5 years of diagnosis could be avoided annually ([@bib1]; [@bib31]).

If analyses are restricted to include only those who survive at least 1 year from diagnosis, then the difference in 5-year survival between England and European countries is, in general, smaller ([@bib39]). Examination of excess mortality in the first year after diagnosis shows that, in particular, it is substantially greater in England than both Norway and Sweden in the first months after diagnosis for breast, colorectal, and lung cancer ([@bib14]; [@bib19]; [@bib23]). This would indicate that the long-term survival differences observed between England and other countries are at least partly a result of a higher number of deaths shortly after diagnosis. Understanding the mechanism that causes these excess deaths could assist in reducing their number, potentially improving long-term outcomes in England.

Recent work shows that the route a patient follows on the way to the diagnosis of their cancer is strongly predictive of 1-year survival ([@bib13]), with those who present as an emergency faring poorly in the first year after diagnosis. In 11 of 15 cancer types examined, emergency presentations (EP) have a 1-year relative survival, which is \>25% lower than those presenting via other routes. [@bib13] shows EPs to be more likely in older patients. One can hypothesise that the lower survival is because of confounding by age and other cofactors generally detrimental to overall health.

Some literature exists on levels of EP internationally, primarily for colorectal cancer. Levels of colorectal EP reported vary: Greece 12% Australia 16% Sweden 17% Canada 24% Norway 25% ([@bib21]; [@bib27]; [@bib41]; [@bib36]; [@bib17]). These studies tend to be based at single centres, comparatively small (\<2000 patients), and based on data stretching back to the 1990s or 1980s. Case finding in secondary care may also overstate the levels of EP compared with population-based studies. Levels of EP in England, at 26% ([@bib13]), appear comparable to or higher than internationally, at least for colorectal cancer. Emergency presentation is an informative measure with regard to death in the first year after diagnosis, and exploration of how EPs occur may help illuminate the difference in 1-year survival between England and comparable countries.

Stage at diagnosis is known to be highly predictive of cancer mortality and later stage at diagnosis is a possible explanation for the difference in cancer survival between England and Europe ([@bib35]; [@bib16]). The completeness of staging data available varies by cancer type and by geographical region of registration. Consequently, this study is confined to cancer types where stage completeness is high enough to be analytically useful and case numbers are high enough for meaningful statistical power. For England as a whole these are colorectal and cervical cancers, and for the East of England (the former Eastern Cancer Registration and Information Centre, ECRIC, registration area) these are breast, lung, and prostate cancers. These cancers have a wide span in the proportion of observed EPs ranging from 5% for breast cancers to 39% for lung cancers; this allows the impact of EP across a range of very different cancer types to be examined.

This study explores the impact of emergency *vs* non-EP routes with two keys aims: to assess the sociodemographic and clinical variables associated with EP; and to test the hypothesis that these cofactors explain the association between EP and short-term mortality.

Materials and methods
=====================

All newly diagnosed invasive tumours excluding non-melanoma skin cancer (ICD-10 C00-C97 excluding C44) diagnosed between 2006 and 2008 in residents of England were extracted from the National Cancer Data Repository (NCDR), with available information on stage at diagnosis ([@bib24]). The NCDR contains all cases of cancer known to the English cancer registries, with a case ascertainment of 98--99% ([@bib22]). Dates of death in the NCDR are derived by record level linkage with ONS mortality records and include all deaths, not just those in hospital. The NCDR data set was de-duplicated using European Network of Cancer Registries criteria ([@bib26]), removing 7% of cases. The 'Route to Diagnosis\' for each case was categorised from routinely available cancer data using a detailed algorithm explained in [@bib13]. The eight possible routes derived there were aggregated here to two categories---EPs and non-EPs. In on 131 754 cases were diagnosed with the cancer types and within the geographical regions of interest. Of these, 2161 cases (1.6%) were excluded on the basis that they were a death certificate only registration; were aged over 99 years at diagnosis; were reported as stage 0 for breast cancer; or had a misordered date of birth, date of diagnosis, and date of death.

The completeness of cancer staging within the NCDR varies strongly with cancer type. For colorectal cancer (ICD-10 codes C18-C20), 68% of cases in England diagnosed in 2006--2008 had a valid Dukes stage recorded. For cervical cancer (ICD-10 C53), 74% of cases in England in the same period had a valid FIGO stage recorded. Cases contributed to the NCDR by the ECRIC had an overall completeness of integrated TNM stage group of 93% (breast cancer: ICD-10 C50), 78% (lung cancer: ICD-10 C33--34), and 95% (prostate cancer: ICD-10 C61).

The Charlson co-morbidity index was created from diagnostic codes (ignoring cancer codes) recorded in the inpatient Hospital Episode Statistics (HES) data set for each patient in the period from 30 months before diagnosis to 3 months before diagnosis. Diagnostic codes relating to independent secondary cancers were sourced from the NCDR over the same period. A Charlson index was derived from these diagnostic codes using a lookup table ([@bib28]). For purposes of generating a Charlson index, the HES records available were limited to those persons with a diagnostic code of cancer recorded at any point in any of their HES records (i.e., all records before diagnosis are available if at least one record contains a cancer code).

The income deprivation quintile was derived by linking each tumour to the Index of Multiple Deprivation 2007 ([@bib8]) using postcode at the time of diagnosis. Equal population quintiles were derived from the income domain score.

Multiple imputation ([@bib25]) was used to generate missing values for stage and co-morbidity. The ice ([@bib33]) and mim ([@bib7]) programs were used to perform imputation in Stata 10.1 ([@bib37]). Imputation was performed on stage and co-morbidity with sex, income deprivation quintile, type of presentation, cancer registry, a binary variable indicating observed metastatic spread or not, age, and survival time included in the imputation model, with no interaction terms. Ten imputed data sets were created.

Sensitivity analysis of the impact of multiple imputation was performed by repeating regression analyses without imputation, with missing cases excluded (a 'completer analysis\'), and by assuming that missing values of stage and co-morbidity took the most extreme plausible values.

Factors predictive of EP were explored through binary logistic regression with the fact of EP as the dependent variable and the demographic and clinical factors as categorical independent variables.

Excess mortality was modelled using the strs program ([@bib11]) in Stata 10.1. Regression analysis used a generalised linear model with a Poisson error structure on collapsed data ([@bib11]), and persons aged \<25 were excluded. Proportional hazards are not assumed because of different variation with time of different cofactors, instead a separate analysis is undertaken for each time period with ordinal independent variables. This ordinal assumption constrains the model to a geometrically increasing series of rate ratios with each increase in one of the independent variables. Sensitivity analyses were performed as for the first regression model.

Results
=======

Over the 3-year period from 2006 to 2008, 131 754 newly diagnosed malignant cancers of interest were diagnosed in England or the ECRIC area. [Table 1](#tbl1){ref-type="table"} shows the number of tumours included and excluded and the proportion of EPs broken down by age, co-morbidity, sex, income deprivation, and the stage at diagnosis for colorectal and cervical tumours at a national level and for breast, lung, and prostate tumours in the ECRIC registration area. Overall, the fraction of EPs increases with age, although for colorectal cancer in particular there is a non-monotonic relationship with a higher fraction presenting as an emergency in those aged 0--24 than those aged 25--64 (albeit with a small cohort size in the younger age group). The proportion of EPs increased with increasing co-morbidity, was higher in women compared with men, and increased with increasing income deprivation.

Across all tumour types, the proportion of EP increased with increasing stage. In early-stage breast, prostate, and cervical cancer, this proportion was \<5%, whereas Dukes A colorectal cancers had 11% EP and TNM stage group 1 lung cancers had 25% EP. For cases without a recorded stage, the proportion of EP was broadly similar to those in cases with a later stage at presentation.

[Figure 1](#fig1){ref-type="fig"} shows excess mortality in five cancer types in the year following diagnosis, for EP and non-EP separately and combined, in persons diagnosed between 2006 and 2008. The excess mortality is substantially higher in EPs, varying between a rate of 162 (prostate cancer); 190 (cervical cancer); 295 (breast cancer); 297 (colorectal cancer); and 635 (lung cancer) deaths per 100 person-years exposure time in the month immediately following diagnosis. In non-EPs, these rates became 5 (prostate and breast cancer); 10 (cervical cancer); 38 (colorectal cancer), and 140 (lung cancer) deaths per 100 person-years. Excess mortality remains elevated for persons presenting by EP in later periods examined and is of comparable magnitude in breast, colorectal, and prostate cancer. Unadjusted excess mortality rate ratios between EP and non-EP cases in the first month after diagnosis are 4.5 (lung cancer), 7.8 (colorectal cancer), 18.5 (cervical cancer), 34.2 (prostate cancer), and 55.1 (breast cancer).

[Table 2](#tbl2){ref-type="table"} shows odds ratios for EP for persons diagnosed between 2006 and 2008. Emergency presentations are more common for younger ages and older ages; more common in women (the lung cancer result is statistically significant at a 95% level); more common in more income-deprived persons; and more common in later-stage cancers. These effects are broadly consistent across all cancer types, with odds ratios for increasing age and stage having the largest magnitudes.

Comparison of odds ratios for EP with and without the use of stage imputation shows either statistically insignificant differences or differences that, although statistically significant, do not greatly change the magnitude of the odds ratios presented (complete case analysis is included in [Supplementary Information](#sup1){ref-type="supplementary-material"}). Pairwise examination of all interaction terms shows some that are statistically significant. However, the change in the odds of EP is small compared with the magnitude of the odds in all but one case. The exception is for patients aged \<25, for which substantial interactions were found.

[Table 3](#tbl3){ref-type="table"} shows excess mortality rate ratios modelled for persons diagnosed between 2006 and 2008. There is a broad consistency across the cancer types examined. The excess mortality rate ratio for EP (compared with non-EP) and increasing age is highest for periods immediately after diagnosis; for increasing stage, the excess mortality rate ratio is highest for later periods. The excess mortality rate ratios for increasing co-morbidity and increasing income deprivation are comparatively small in magnitude compared with those of stage and age, and those for sex (for lung and colorectal cancer) are close to unity.

The dependence of excess mortality rate ratios on EP for the month after diagnosis are highest for prostate and breast cancer, and lower for lung and colorectal cancer. Prostate cancer shows the highest dependence on age and breast cancer on stage in this same month.

Regression coefficients recalculated after excluding stage 1--3 prostate cancer, stage 1--2 breast cancer, and stage 1 cervical cancer were not statistically significantly different from those presented in [Table 3](#tbl3){ref-type="table"}, although the rate ratio of the excess mortality for prostate cancer in the first month after diagnosis was reduced to 11.8 (95% confidence interval: 5.2--26.9). Pairwise examination of all interaction terms shows some that are statistically significant. However, the change in the excess mortality rate ratio because of EP is small compared with its magnitude in all cases. The model for cervical cancer was mildly improved by including an interaction term between stage and age. Comparison of excess mortality rate ratios with and without the use of stage imputation shows either statistically insignificant differences or differences that, although statistically significant, do not greatly change the magnitude of the rate ratios presented (complete case analysis is included in [Supplementary Information](#sup1){ref-type="supplementary-material"}).

Discussion
==========

This study presents a two-step analysis of EP of cancer, as categorised from routinely available health service data. We show EP to be highly predictive of cancer mortality in the year following diagnosis, and especially in the month following diagnosis. That EPs were more common with older age and more advanced stage was expected: we demonstrate a case-mix effect in the frequency of EP because of stage and age at presentation across all cancer types examined with a lesser effect owing to co-morbidity, deprivation, and female sex (where relevant). Excess mortality was strongly associated with EP, independently of case-mix factors, disproving the hypothesis that it is because of these factors alone.

Strengths and weaknesses
------------------------

An advantage of using routine data is the population basis of the patient cohort, thereby representing all cancers diagnosed (and without demanding additional intrusive patient contact). The ECRIC registration area has a population of around 5.5 million (similar to Scotland, Denmark, and Norway) and has overall cancer survival comparable to that of England ([@bib29]). The fraction of EPs in the ECRIC area for breast, lung, and prostate cancer is similar to that for England as a whole ([@bib13]). Cancer staging within the ECRIC registration area is to a consistent standard and of high completeness. Together, these observations support an argument that the results for the ECRIC area, especially once adjusted for case-mix, are robust and applicable to the broader English population.

The independent variables selected (age, sex, and income deprivation) cover major demographic causes for variation in mortality, as well as clinical causes attributed to the cancer itself (stage) and pre-existing health (co-morbidity). Performance status was not available as an independent variable, but one could anticipate that age and co-morbidity may act as a partial proxy factors for it.

Age, sex, and income deprivation are recorded with high completeness. One can criticise the assignment of the income deprivation score on the grounds of the ecological fallacy, as the lower super output areas used to assign a quintile have an average population of around 1600 persons. This may have the effect of reducing the observed impact of income deprivation compared to the actual impact. Stage and co-morbidity data are to some extent incomplete, as shown in [Table 1](#tbl1){ref-type="table"}. Reasons for missing stage data might be treatment outside NHS secondary care, death before staging was complete, or a lack of data transfer to cancer registries of key data (e.g. nodal status) needed to compute a stage. Co-morbidity data are missing because of the absence of an available HES record in the period before diagnosis. The variables in the imputation model can be expected to be sensitive to these different mechanisms and therefore make the missing at random assumption plausible.

There are several assumptions built into the assignment of a co-morbidity score. As scores are drawn from previous inpatient admissions they will not count anyone with a significant condition that is treated exclusively in outpatient or primary care, and they also only count those with an inpatient admission in the designated period. It is therefore plausible then that the influence of co-morbidity is under-represented in this study to a degree, although the higher the degree of decompensation from co-morbidity (in the years immediately before diagnosis) the more likely that this fact will be captured.

Overall, as far as can be determined, the results are methodologically robust. Sensitivity analyses show that the relationships between the likelihood of EP and the independent variables examined, and between EP and short-term mortality are not greatly affected by the imputation performed. The one substantial interaction term found in the model for the likelihood of EP -- for persons aged \<25 -- is itself a plausible exception because of the very different referral pathways for these patients. Modelling the excess mortality rate ratios using ordinal independent variables gives good agreement with a similar, but categorical, model for colorectal cancer ([@bib12]).

Variation in mortality
----------------------

The overall (unadjusted) excess mortality observed in [Figure 1](#fig1){ref-type="fig"} is consistent with other studies in magnitude and in variation over time following diagnosis for breast, colorectal, and lung cancer ([@bib14]; [@bib19]; [@bib23]). All show higher excess mortality in the first months after diagnosis, which quickly falls off towards the end of the first year after diagnosis. However, the variation in excess mortality between EPs and non-EPs in the period immediately after diagnosis (0--1 month for breast cancer and 0--3 months for lung and colorectal cancer) is greater than that between the youngest and oldest age groups in prior studies. Patients presenting as emergencies with breast, cervical, colorectal, or prostate cancer experience higher mortality in the first month after diagnosis than those presenting with lung cancer as non-emergencies.

The impact of EP on short-term mortality observed here is consistent with that in other studies. A wide literature exploring this association exists for colorectal cancer, (e.g. [@bib15]; [@bib12]), but few studies exist for other cancer types. It has been shown that mortality within 30 days of a diagnosis of breast (and colorectal) cancer is associated with an emergency admission within 30 days before or after diagnosis ([@bib5]). Moreover, a case finding study of cancer patients across all tumour types in Northern Ireland who died in hospital ([@bib3]) showed that 79% of deaths followed emergency admissions (this included admissions with previously known cancers as well as EP via an emergency inpatient admission).

Multivariate modelling of the excess mortality rate ratio to take into account selected case-mix factors showed that, as for the unadjusted case, the impact of EP was most marked in the first month after the diagnosis ([Table 3](#tbl3){ref-type="table"}). We saw a range in adjusted excess mortality rate ratios between 4.0 (lung) and 20.8 (prostate cancer). The impact of EP fell with time, although EPs still carried a higher risk of mortality at later periods, even when other factors were accounted for. In contrast, the impact of stage on excess mortality either stayed broadly the same within the different time intervals (cervical cancer) or increased with the time since diagnosis (breast, colorectal, lung, and prostate cancer). This difference in the dependence of excess mortality rate ratios on time implies that the causes of mortality following EP are more complex than a simple dependence on tumour stage.

For lung and colorectal cancer, case-mix had a comparatively small effect on the excess mortality rate ratio for EP compared with non-EP in the first month after diagnosis. For breast, cervical, and prostate cancer, the adjusted mortality rate ratio in the first month after diagnosis is reduced compared with the unadjusted figure, but still substantial and comparable to or greater in magnitude than the effect of stage or age. In contrast, the low dependence of the excess mortality rate ratios on sex and income deprivation suggests that patient demographics are of more importance in determining the route of presentation than the subsequent mortality within that route.

The fraction of excess mortality in the first month because of EP alone can be estimated: if the multivariate model is adjusted such that the excess mortality rate ratio for EP is 1.0, while holding other rate ratios constant, we then predict that the excess mortality in the first month falls to between 30 and 50% of the observed figure for all five cancer types. This simple approach overestimates the impact of EP as it would not account for the deaths which would then be expected to take place in the additional patient exposure time introduced, but it suggests that the contribution of EP to mortality in the first month following diagnosis is of the order of a half. A better estimate of the impact of EP requires a better understanding of their nature.

The nature of EP
----------------

Emergency presentation can be viewed as an extreme expression of the waiting time paradox ([@bib9]; [@bib38]) where the outcomes are poor but the 'waiting time\' is very short. The hypotheses to explain these poor outcomes that go beyond the influence of the independent variables already considered are of great interest. These can be broadly summarised as:

First, residual confounding by independent variables not considered (such as performance status) or imperfectly defined (co-morbidity or income deprivation) is a possibility. However, it is difficult to explain the magnitude of the excess mortality rate ratios for EP in the first month after diagnosis via this mechanism.

Second, mortality is because of other co-morbidities with a sudden onset, that is, the cancers are being diagnosed incidentally as an emergency. However, it was estimated that only 1 in 19 to 1 in 15 of calculated presentation routes are because of incidental admissions ([@bib13]), only some of which will be emergencies. The (low) proportion of EP in early-stage breast and prostate cancer could be explained by this mechanism but sensitivity analysis, which excludes early-stage tumours from the analysis shows little impact on the observed dependence of excess mortality on EP, implying that this is not a major overall influence.

Third, EPs occur preferentially with advanced complications ([@bib18]), or EP tumours are preferentially faster growing or otherwise associated with higher mortality (e.g., because of physical location in an organ). The nature of the tumour, beyond its stage, plausibly affects both route of presentation and the short-term outcome. For example, colorectal tumours that cause an obstruction or perforation of the bowel are likely to be EPs with poor outcomes. Further confounding is also possible: colorectal tumours presenting higher in the colon are likely to be more frequently EPs (because of less specific symptoms) and to have worse outcomes (because of the comparative inaccessibility).

Fourth, excess mortality is because of presentation at night or on weekends or to non-specialist centres where clinical services are less available or less capable. An emergency inpatient admission (which occurs during the majority of EPs) caused by cancer can occur for disparate reasons including metabolic emergencies, cardiovascular emergencies, infectious emergencies, and respiratory emergencies ([@bib20]). They are challenging to manage with the potential for rapidly deleterious effects ([@bib34]; [@bib32]). In these circumstances, excess mortality could be due to either the absence of (or delay to) specialist care or due to iatrogenic causes.

The widespread impact of EP on 1-year cancer survival ([@bib13]), the lack of sensitivity to case-mix adjustment in lung and colorectal cancer, and the uniformly high (unadjusted) excess mortality rates in EPs suggest that a common mechanism, or mechanisms, may be at work for all cancers. Overall, this study is consistent with a mixture primarily of the third and fourth hypotheses.

Improving outcomes
------------------

The mortality associated with EP might be reduced by reducing the number of EPs -- an aim closely aligned with early presentation in general. How achievable this is depends on the frequency of symptoms before those that directly lead to the presentation; in some cases EP might be inevitable, perhaps where no prior symptoms are felt before a critical event. Overall, the progression of symptoms experienced leading up to a diagnosis of cancer is not well understood. In some cases, EP can be the most clinically appropriate diagnostic route, such as for some acute haematological cancers. The frequency of EP in lung cancer can be reduced through public awareness campaigns ([@bib6]), potentially reducing the associated mortality. It has been shown that emergency admissions with rapid mortality are more likely in those not living with a partner ([@bib3]) and the likelihood of EP has been associated with several characteristics of the patient\'s general practice ([@bib4]). This suggests that interventions by primary and social care may be effective in reducing the number of EPs. In primary care, these interventions might be, for example, significant event audits targeting EPs and subsequent review of referral practice, perhaps similar to recent recommendations for the management of existing cases of cancer to prevent emergency admissions ([@bib32]).

Mortality could also be reduced by seeking to reduce the impact of EP, the extent to which this can be achieved depends on the balance between the share of the excess mortality that is due to the nature of the tumour and the extent because of care delivered in emergency settings. The latter could be affected by detailed examination of causes of death in these cases and subsequent change of practice in secondary care.

In summary, EP is a strongly predictive leading indicator of short-term mortality following cancer diagnosis. Although EPs are more frequent in older persons with advanced cancers and extensive co-morbidities, these factors do not fully explain the impact of EP on excess mortality. In particular, EP remains highly predictive of very short (\<1 month) mortality. Further work to test hypotheses for this association could potentially lead to significant reductions in mortality immediately following diagnosis, in which England fares poorly in international comparisons. This might take the form of linkage to primary care data to investigate patient\'s interaction with a GP before an EP. The extension of the Routes to Diagnosis algorithm to international data sets may also illuminate causal factors that lead to EP.
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![**Unadjusted excess mortality rates for emergency (dotted), non-emergency (dashed), and all presentation (solid) routes in the periods 0--1, 1--3, 3--6, and 6--12 months after diagnosis, plotted semilogarithmically at the central point of those periods with 95% confidence intervals.** Figures represent all persons diagnosed with selected cancer types in England (cervical and colorectal cancer) and the ECRIC registration area (breast, lung, and prostate cancer), 2006--2008. Stage and co-morbidity include imputed values.](bjc2013569f1){#fig1}

###### Numbers of cancers and proportions diagnosed via EP for persons resident in England (cervical and colorectal) and the ECRIC registration area (breast, lung, and prostate) diagnosed in 2006--2008

                            **England**  **ECRIC registration area**                                                                               
  ------------------------ ------------- ----------------------------- ----------- -------- ----- ----------- -------- ----- ------ ----- -------- -----
  **Number**                                                                                                                                       
  *n*                          6950      12%                                        89 484  26%                12 354   4%    9601   36%   11 204   7%
  Excluded                      50       ---                                         1932   ---                  79     ---    71    ---     29     ---
  **Age**                                                                                                                                          
  0--24                         151      11%                                         159    58%                  9      0%     3     0%      0      ---
  25--64                       5264      8%                                         24 283  20%                 6797    1%    2370   29%    2553    3%
  65--84                       1251      22%                                        54 026  24%                 4545    5%    6087   36%    7677    6%
  85+                           284      41%                                        11 016  43%                 1003    16%   1141   54%    974     26%
  **Co-morbidity**                                                                                                                                 
  Not known                     982      5%                                          5723   26%                 1744    4%    1035   31%    3088    4%
  0                            5569      13%                                        71 274  24%                 9822    4%    6829   36%    6894    7%
  1                             243      21%                                         6708   34%                 513     7%    979    41%    680     11%
  2                             103      26%                                         3777   31%                 190     7%    453    41%    364     14%
  3+                            53       36%                                         2002   40%                  85     9%    305    43%    178     13%
  **Sex**                                                                                                                                          
  Male                          ---      ---                                        49 515  23%                 ---     ---   5602   35%   11 204   7%
  Female                       6950      12%                                        39 969  29%                12 354   4%    3999   38%    ---     ---
  **Income deprivation**                                                                                                                           
  Least deprived               1089      8%                                         18 349  22%                 2962    3%    1579   33%    2725    5%
  2                            1243      11%                                        20 087  24%                 3334    4%    2170   34%    3081    6%
  3                            1338      13%                                        19 398  25%                 3058    4%    2583   36%    2933    8%
  5                            1489      12%                                        17 459  27%                 2229    5%    2251   39%    1859    8%
  Most deprived                1791      15%                                        14 191  31%                 771     5%    1018   40%    606     10%
  **Stage**                                                                                                                                        
  Not known                    1823      19%                           Not Known    28 449  30%   Not Known     922     11%   2154   41%    527     18%
  FIGO 1                       3324      3%                            A (Dukes)     8718   8%    TNM 1         4754    1%    1115   21%     51     2%
  FIGO 2                        906      14%                           B (Dukes)    21 652  22%   TNM 2         5113    2%    462    19%    7794    3%
  FIGO 3                        490      24%                           C (Dukes)    21 498  26%   TNM 3         1013    8%    2491   31%    1270    4%
  FIGO 4                        407      41%                           D (Dukes)     9167   36%   TNM 4         552     29%   3379   44%    1562    23%
  **Imputed stage**                                                                                                                                
  FIGO 1                       4359      4%                            A (Dukes)    12 651  11%   TNM 1         5118    1%    1564   25%     54     3%
  FIGO 2                       1278      16%                           B (Dukes)    31 569  23%   TNM 2         5554    3%    686    26%    8244    4%
  FIGO 3                        730      29%                           C (Dukes)    33 283  29%   TNM 3         1130    11%   3969   36%    1343    5%
  FIGO 4                        584      45%                           D (Dukes)    11 981  37%   TNM 4         552     29%   3382   44%    1562    23%

Abbreviations: ECRIC=Eastern Cancer Registration and Information Centre; EP=emergency presentations; TNM=tumour node metastasis stage group; FIGO = International Federation of Gynecology and Obstetrics stage.

###### Odd ratios for emergency presentation and 95% CIs from a multivariate logistic model

                            **England**   **ECRIC area**                                                                                     
  ------------------------ ------------- ---------------- --------- ----- ------------ ------- ------ ------------- ----- ------------ ----- ------------
  **Sex**                                                                                                                                    
  Male                          ---                                 1.0                         ---                 1.0                 ---        
  Female                        ---            ---                  1.3    (1.2--1.3)           ---        ---      1.1    (1.0--1.2)   ---      ---
  **Stage**                                                                                                                                  
  FIGO 1                        1.0                       Dukes A   1.0                TNM 1    1.0                 1.0                 0.6   (0.1--5.4)
  FIGO 2                        3.7         (2.8--4.9)    Dukes B   2.3    (2.2--2.5)  TNM 2    1.1    (0.2--4.6)   1.1    (0.8--1.5)   1.0        
  FIGO 3                        7.4        (5.3--10.3)    Dukes C   3.3    (3.1--3.6)  TNM 3    3.7    (0.9--16.0)  1.8    (1.5--2.1)   1.3   (1.0--1.8)
  FIGO 4                       14.7        (11.1--19.6)   Dukes D   4.8    (4.5--5.2)  TNM 4    13.9   (3.2--59.7)  2.7    (2.4--3.2)   5.9   (5.0--7.0)
  **Age**                                                                                                                                    
  0--24                         1.5         (0.9--2.7)              5.5    (4.0--7.6)           ---                 ---                 ---        
  25--64                        1.0                                 1.0                         1.0                 1.0                 1.0        
  65--84                        1.5         (1.2--1.8)              1.3    (1.2--1.3)           3.5    (2.7--4.6)   1.4    (1.2--1.5)   1.5   (1.2--1.9)
  85+                           2.9         (2.1--3.9)              2.8    (2.6--2.9)           11.1   (8.3--14.8)  3.1    (2.7--3.6)   7.0   (5.4--9.2)
  **Co-morbidity**                                                                                                                           
  Charlson 0                    1.0                                 1.0                         1.0                 1.0                 1.0        
  Charlson 1                    1.1         (0.8--1.6)              1.5    (1.4--1.6)           1.3    (0.8--2.0)   1.2    (1.0--1.4)   1.2   (0.9--1.5)
  Charlson 2                    1.5         (0.9--2.5)              1.4    (1.3--1.5)           1.4    (0.7--2.8)   1.3    (1.1--1.6)   1.8   (1.2--2.7)
  Charlson 3+                   1.6         (0.9--3.1)              2.0    (1.8--2.2)           1.3    (0.6--2.8)   1.4    (1.1--1.8)   1.5   (0.9--2.5)
  **Income deprivation**                                                                                                                     
  Least deprived                1.0                                 1.0                         1.0                 1.0                 1.0        
  2                             1.3         (1.0--1.8)              1.1    (1.0--1.1)           0.9    (0.7--1.3)   1.0    (0.9--1.2)   1.0   (0.8--1.3)
  3                             1.4         (1.1--1.9)              1.2    (1.1--1.2)           1.0    (0.8--1.4)   1.2    (1.0--1.3)   1.3   (1.0--1.7)
  4                             1.3         (1.0--1.8)              1.3    (1.2--1.3)           1.2    (0.9--1.6)   1.3    (1.1--1.5)   1.4   (1.1--1.7)
  Most Deprived                 1.6         (1.2--2.2)              1.6    (1.5--1.7)           1.2    (0.8--1.9)   1.4    (1.2--1.6)   1.7   (1.2--2.4)

Abbreviations: CI=confidence interval; ECRIC=Eastern Cancer Registration and Information Centre; OR=odds ratio.

Persons resident in England (cervical and colorectal) or the ECRIC registration area (breast, lung, and prostate) diagnosed in 2006--2008. Stage and co-morbidity include imputed values.

###### Excess mortality rate ratios and 95% confidence intervals at 0--1, 1--3, 3--6, and 6--12 months after diagnosis from a multivariate model

                       **England**   **ECRIC registration area**                                                                     
  -------------------- ------------- ----------------------------- ----- ------------ ------ ------------- ----- ------------ ------ --------------
  **0--1 month**                                                                                                                     
  Presentation route   7.5           (4.9--11.1)                   5.9   (5.6--6.2)   11.7   (7.8--17.4)   4.0   (3.7--4.4)   20.8   (11.7--36.3)
  Age                  2.0           (1.6--2.5)                    2.1   (2.0--2.2)   1.9    (1.5--2.4)    1.6   (1.4--1.7)   3.0    (2.1--4.2)
  Co-morbidity         1.3           (1.0--1.6)                    1.2   (1.1--1.2)   1.4    (1.0--1.8)    1.1   (1.0--1.1)   1.4    (1.1--1.8)
  Sex                  ---           ---                           1.1   (1.0--1.1)   ---    ---           0.9   (0.8--0.9)   ---    ---
  Income deprivation   0.9           (0.8--1.0)                    1.1   (1.0--1.1)   1.0    (0.9--1.2)    1.0   (1.0--1.1)   1.1    (0.9--1.3)
  Stage                1.7           (1.4--2.1)                    1.5   (1.4--1.5)   3.0    (2.4--3.7)    1.2   (1.2--1.3)   1.0    (0.8--1.3)
  **1--3 months**                                                                                                                    
  Presentation route   2.3           (1.7--3.1)                    2.4   (2.3--2.6)   3.2    (1.9--5.3)    2.4   (2.2--2.6)   5.2    (3.4--8.0)
  Age                  2.1           (1.7--2.6)                    1.9   (1.8--2.0)   2.3    (1.6--3.2)    1.4   (1.3--1.5)   2.7    (1.9--3.9)
  Co-morbidity         1.2           (1.0--1.4)                    1.2   (1.1--1.2)   1.1    (0.5--1.9)    1.1   (1.0--1.2)   1.3    (1.0--1.6)
  Sex                  ---           ---                           1.0   (1.0--1.1)   ---    ---           1.0   (0.9--1.1)   ---    ---
  Income deprivation   1.1           (1.0--1.2)                    1.1   (1.0--1.1)   1.0    (0.8--1.2)    1.0   (1.0--1.0)   1.1    (0.9--1.3)
  Stage                2.2           (1.8--2.5)                    2.2   (2.1--2.2)   5.2    (3.6--7.5)    1.6   (1.5--1.7)   2.9    (2.2--4.0)
  **3--6 months**                                                                                                                    
  Presentation route   2.3           (1.7--3.1)                    1.8   (1.7--1.9)   2.3    (1.3--4.0)    1.7   (1.5--2.0)   6.6    (4.0--10.8)
  Age                  2.2           (1.8--2.7)                    1.8   (1.7--1.9)   2.0    (1.4--2.9)    1.4   (1.3--1.5)   1.9    (1.2--2.8)
  Co-morbidity         1.2           (0.9--1.5)                    1.3   (1.2--1.3)   1.8    (1.3--2.4)    1.1   (1.0--1.2)   1.9    (1.6--2.3)
  Sex                  ---           ---                           1.1   (1.0--1.2)   ---    ---           0.9   (0.8--1.0)   ---    ---
  Income deprivation   1.0           (0.9--1.1)                    1.1   (1.0--1.1)   1.3    (1.0--1.5)    1.0   (1.0--1.1)   0.9    (0.8--1.1)
  Stage                2.3           (1.9--2.7)                    2.6   (2.4--2.7)   5.1    (3.7--7.0)    1.8   (1.6--1.9)   2.2    (1.7--3.0)
  **6--12 months**                                                                                                                   
  Presentation route   2.7           (2.2--3.4)                    1.7   (1.6--1.8)   2.1    (1.4--3.3)    1.3   (1.2--1.5)   2.5    (1.6--4.0)
  Age                  1.6           (1.3--1.9)                    1.5   (1.4--1.6)   1.9    (1.5--2.4)    1.3   (1.2--1.5)   1.0    (0.7--1.5)
  Co-morbidity         1.2           (1.0--1.4)                    1.3   (1.2--1.3)   1.7    (1.3--2.1)    1.0   (0.9--1.1)   1.4    (1.1--1.8)
  Sex                  ---           ---                           1.1   (1.0--1.2)   ---    ---           0.9   (0.9--1.0)   ---    ---
  Income deprivation   1.1           (1.0--1.2)                    1.0   (1.0--1.1)   1.0    (0.9--1.2)    1.0   (1.0--1.0)   1.0    (0.9--1.2)
  Stage                2.2           (1.9--2.4)                    3.1   (2.9--3.2)   4.1    (3.4--4.9)    1.7   (1.6--1.9)   7.5    (3.3--17.0)

Abbreviations: CI=confidence interval; ECRIC=Eastern Cancer Registration and Information Centre; EMRR=excess mortality rate ratio.

Rate ratios show the increase in excess mortality in the period per step increase in presentation (non-emergency or emergency), age (25--64, 65--84, or 85+), co-morbidity (Charlson 0, 1, 2, 3+), sex (male or female), income deprivation (quintiles from least to most income deprivation), or stage (increasing FIGO, Dukes, or TNM-integrated stage on a four-point scale). The model included persons resident in England (cervical and colorectal cancer) or the ECRIC registration area (breast, lung, and prostate cancer) diagnosed in 2006--2008. Stage and co-morbidity include imputed values.
